Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

257318 items
12:00 AM, Jun 13, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

ImmuRAID-AFP antibody fragment targeted to alpha fetal protein data

In an investigator-initiated trial in 45 patients with a total of 169 tumor sites, the agent gave 75 percent specificity, 99 percent sensitivity, and 90 percent accuracy. No side effects or HAMA responses were encountered....
12:00 AM, Jun 13, 1994  |  BC Week In Review | Company News  |  Deals

Receptagen deal

RCG acquired Vancouver Wholesale Drugs Ltd., a privately held wholesaler of prescription drugs, for C$5.5 million. Vancouver Wholesale, which will operate as a wholly owned subsidiary of Vancouver-based RCG, posted net income of C$1.7 million...
12:00 AM, Jun 13, 1994  |  BC Week In Review | Company News  |  Deals

Cangene deal

(Pharma Patch bid for CNJ, see B6) Cangene Corp. (TSE:CNJ)   3Q ended April 30: Royalties from the sale of Nucleic Acid Sequence-Based Amplification technology by partner Organon Teknika rose to $125,000 from $100,000 in the...
12:00 AM, Jun 13, 1994  |  BC Week In Review | Clinical News  |  Regulatory

LifeCell regulatory update

LifeCell Corp. (LIFC)   The Woodlands, Texas, company received notice of allowance for a U.S. patent relating to its Universal Tissue Process technology, which removes immunogenic components from tissue grafts without altering or damaging the biochemical...
12:00 AM, Jun 13, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Modified retrovirus: The trial will begin on final approval from the FDA.

University of Pittsburg Medical Center   Product: Modified retrovirus bearing the gene for interleukin-1 receptor antagonist protein (IRAP)   Indication: Rheumatoid arthritis   Status: University researchers received approval from the Recombinant DNA Advisory Committee to test the...
12:00 AM, Jun 13, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Biocircuits regulatory update

BIOC (Sunnyvale, Calif.) received notices of allowance for two U.S. patents relating to technology used in its IOS immunodiagnostic system, a point-of-care test that determines T4 and T Uptake for determining thyroid dysfunction. One allowance...
12:00 AM, Jun 06, 1994  |  BC Week In Review | Company News  |  Other News

Deprenyl Animal Health Inc. news

The companies worked together on cognitive dysfunction in animals in 1991. The work was terminated by Orion after one year for lack of interest in the field, according to David Stevens, DAHI's president and CEO....
12:00 AM, Jun 06, 1994  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Genentech Inc. (GNE) Oppenheimer's Geller also began coverage of GNE with a "market performer" rating. He said the South San Francisco company probably has the deepest, most promising pipeline in the sector. He said that...
12:00 AM, Jun 06, 1994  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Biogen Inc. (BGEN) PaineWebber analyst Linda Miller maintained her "attractive" rating, but lowered her second quarter and 1994 and 1995 EPS estimates. She said expenses will likely exceed her earlier forecasts because of increased costs...
12:00 AM, Jun 06, 1994  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Amgen Inc. (AMGN) Matthew Geller of Oppenheimer & Co. initiated coverage of Amgen Inc. with a "market performer" rating and a one-year target of $56. He said the fiscal conservatism of the Thousand Oaks, Calif.,...

Pages